Compare UTSI & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UTSI | QNCX |
|---|---|---|
| Founded | 1991 | 2012 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 19.9M |
| IPO Year | 1999 | 2019 |
| Metric | UTSI | QNCX |
|---|---|---|
| Price | $2.95 | $0.91 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.9K | ★ 1.4M |
| Earning Date | 03-24-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.34 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.00 | $0.08 |
| 52 Week High | $2.94 | $4.55 |
| Indicator | UTSI | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 64.09 | 38.84 |
| Support Level | $2.34 | $0.79 |
| Resistance Level | N/A | $0.98 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 94.12 | 0.56 |
UTStarcom Holdings Corp is providing telecommunication network products, solutions and services. It focus on delivering carrier-class packet optical, network synchronization and broadband access (both wireless and fixed line) products and solutions, coupled with Software Defined Networking (SDN) platform, optimized for mobile backhaul, metro aggregation, broadband access and value added services. The business activity of the firm is operated through the Equipment and Service segment. The Equipment segment is focused on equipment sales, including network infrastructure and application products, and the Service segment is engaged in providing services and support of equipment products and also the new operational support. Key revenue is generated from Equipment segment.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.